BioCryst Pharmaceuticals | BCRX - Cash And Equivalent


BioCryst Pharmaceuticals reported $84.08M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Alnylam Pharmaceuticals USD 1.66B 167M Dec/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Chugai Pharma JPY 456.43B 40.66B Sep/2025
Daiichi Sankyo JPY 542.16B 97.68B Sep/2025
DBV Technologies USD 69.84M 33.37M Sep/2025
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Ionis Pharmaceuticals USD 2.68B 437M Dec/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
Neurocrine Biosciences USD 713M 372.8M Dec/2025
Novavax USD 268.02M 14.28M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025